Migralepsy and related conditions: Advances in pathophysiology and classification  by Verrotti, Alberto et al.
Seizure 20 (2011) 271–275Review
Migralepsy and related conditions: Advances in pathophysiology and
classiﬁcation
Alberto Verrotti a, Pasquale Striano b, Vincenzo Belcastro c, Sara Matricardi a, Maria Pia Villa d,
Pasquale Parisi d,*
aChild Neurology and Department of Pediatrics, University of Chieti, Italy
bMuscular and Neurodegenerative Diseases Unit, G. Gaslini Institute, University of Genova, Italy
cNeurology Clinic, Department of Neuroscience, Sant’Anna Hospital, Como, Italy
dChild Neurology, Pediatric Headache Centre, Sleep Disorders Centre, Chair of Pediatrics, Second, Faculty of Medicine, ‘‘Sapienza’’ University, Via di Grottarossa,
1035-1039, 00189 Rome, Italy
A R T I C L E I N F O
Article history:
Received 5 January 2011
Received in revised form 8 February 2011








A B S T R A C T
Basic and clinical neuroscience research ﬁndings suggest that cortical spreading depression (CSD) and
epileptic focimay facilitate each other; furthermore, the threshold required for the onset of CSD has been
suggested to be lower than that required for an epileptic focus. These data may explain the prevalence of
epilepsy in migraine populations (ranging from 1% to 17%) and the frequency of migraine in epileptic
populations (ranging from 8.4% to 20%). There is currently a considerable amount of confusion regarding
this topic in both headache and epilepsy classiﬁcations (ICHD-II and ILAE). The ICHD-II includes
‘‘migraine-triggered seizure’’ (coded as ‘‘1.5.5’’) (so-called ‘‘migralepsy’’) among the ‘‘complications of
migraine’’, and deﬁnes ‘‘hemicrania epileptica’’ (‘‘7.6.1’’) as an ‘‘ictal headache’’ (ipsilateral to the ictal
EEG discharge) that occurs ‘‘synchronously’’ with a seizure (partial epileptic seizure) recognized by ILAE
classiﬁcation. However, neither ‘‘migralepsy’’ nor ‘‘hemicrania epileptica’’ are terms used in the current
ILAE classiﬁcation. On the basis of data reported in the literature and our recent ﬁndings, we suggest that
the terms ‘‘migraine-triggered seizure’’ and ‘‘migralepsy’’ be deleted until unequivocal evidence of the
existence of these conditions emerges. ‘‘Ictal epileptic headache’’ (IEH) should be used to classify those
rare events in which headache represents the sole ictal epileptic manifestation. On the other hand, the
term ‘‘hemicrania epileptica’’ should be maintained in the ICHD-II and introduced into the ILAE, and be
used to classify all cases in which an ‘‘ictal epileptic headache’’ ‘‘coexists’’ and is associated
synchronously or sequentially with other ictal sensory-motor events.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The clinically based hypothesis that migraine and epilepsy are
related dates back to the 19th century.1 Both disorders are
characterized by transient paroxysmal episodes of altered brain
function with a clinical, pathophysiological and therapeutic
overlap.2
The prevalence of migraine is low in childhood, peaks in adult
age and decreases in old age, whereas the incidence of epilepsy is
highest in childhood and old age.3 Nevertheless, there is a strong
epidemiological association between these two conditions, and the* Corresponding author at: Child Neurology, Headache Paediatric Center,
Paediatric Sleep Disorders, Chair of Paediatrics, II Faculty of Medicine, ‘‘Sapienza’’
University, c/o Sant’Andrea Hospital, Via di Grottarossa, 1035-1039 Rome, Italy.
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1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.02.012occurrence of both disorders in the same individual is more
frequent than is to be expected on the basis of a chance occurrence.
Indeed, the prevalence of epilepsy in the population of migraine
sufferers ranges, depending on the study, from 1% to 17%, with a
median of 5.9%,4 which is signiﬁcantly higher than the prevalence
of epilepsy in the general population (0.5–1%).3 Moreover, the
frequency of migraine in the epilepsy population is high, ranging
from 8.4% to 20%.1
Over the last decade, the possible common pathophysiological
mechanisms underlying these two conditions have received a
considerable amount of attention. Many of the studies that have
been conducted support the hypothesis of excessive neocortical
cellular excitability as the main pathological mechanism underly-
ing the onset of both diseases.2 In migraine, however, hyperexcit-
ability is believed to transition to cortical spreading depression
rather than to the hypersynchronous activity that characterizes
epilepsy. Notably, some forms of epilepsy and migraine are known
to be channelopathies.2 Mutations in the same genes can causevier Ltd. All rights reserved.
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given the likely commonalities in the underlying cellular and
molecular mechanisms, it is hardly surprising that some antiepi-
leptic drugs (AEDs), including valproate, topiramate and gaba-
pentin, are also effective as antimigraine agents.5 Ionotropic
glutamate receptors are involved in both migraine and epilepsy,
with NMDA receptors, which are critical to cortical spreading
depression, playing a particularly important role in migraine.5
Migralepsy is a rare condition in which a migraine attack is
followed, within an hour, by an epileptic seizure.4,6,7 However, the
diagnosis of this condition is extremely challenging, as is the task
of differentiating it from epileptic seizures.8–11 In recent years, the
inaccuracy of the current deﬁnition and classiﬁcation of migra-
lepsy and conditions related to migralepsy has become increas-
ingly apparent.10–14
2. Deﬁnitions
The term ‘migralepsy’ was ﬁrst used in 1960 by Lennox &
Lennox (who quoted Dr Douglas Davison) to describe a condition
wherein ‘‘ophthalmic migraine with perhaps nausea and vomiting
was followed by symptoms characteristic of epilepsy’’.7 Since then,
approximately 50 cases have been described in the literature, the
majority of which have been the criticized by other authors.10–14 It
is surprising that so few case reports have been published despite
the fact that migraine and epilepsy are among the most common
brain diseases.12 Indeed, most of the cases of ‘‘migralepsy’’ that
have been reported are either complex cases that do not provide
unequivocal evidence of an association between migraine and
epilepsy or occipital seizures imitating migraine with aura.8,9
Migralepsy does not exist in previous classiﬁcations of the
International League Against Epilepsy (ILAE) or in the recent report
of the ILAE Commission on the Classiﬁcation and Terminology of
seizures and epilepsies15; however, according to the current
International Classiﬁcation of Headache Disorders II (ICHD-II),16
migralepsy is included among the complications of migraine
(paragraph coded 1.5.5.) and is deﬁned as a migraine triggered-
seizure that must fulﬁll two diagnostic criteria: (a) migraine
fulﬁlling the criteria for 1.2 Migraine with aura (MwA); (b) a
seizure fulﬁlling the diagnostic criteria for one type of epileptic
attack that occurs within 1 h of a migraine aura.16
Migralepsy is different from ‘hemicrania epileptica’, which is
deﬁned in the ICHD-2 classiﬁcation (International Headache
Society, 2004) (coded as 7.6.1) as an ‘‘ictal headache’’ (ipsilateral
to the ictal EEG discharge) that occurs ‘‘synchronously’’ with a
seizure (partial epileptic seizure) included in the ILAE classiﬁca-
tion. The term ‘‘ictal epileptic headache’’ has recently been
proposed by Parisi et al. 17–21 and deﬁned as ‘‘the sole ictal
epileptic phenomenon’’ without any other associated ictal epilep-
tic signs/symptoms recognized by the ILAE.
Sances et al. 12 recently provided a demonstration of the
inadequacy of the current deﬁnition of migralepsy:MwA includes a
variety of MwA subtypes (typical aura with migraine headache,
typical aura with non-migraine headache, typical aura without
headache, familial hemiplegic migraine, sporadic hemiplegic
migraine, and basilar-type migraine), though none of these has
been associated with migralepsy. In addition, migralepsy may even
be triggered bymigrainewithout aura (MwoA) attacks ormay occur
later than the 1-h post-aural time-frame stipulated by the ICHD-II
criteria.13 Sances et al. thus suggested that the deﬁnition of
migralepsy should only include those types of migraine that are
reported to be associated with the migralepsy clinical picture;
moreover, they recommended that the ICHD-II deﬁnitionbe revised,
relocating migralepsy from the ‘‘complications of migraine’’
paragraph to the ICHD-II Appendix (where novel entities that have
not been sufﬁciently validated by research studies are classiﬁed).3. Clinical, EEG and neuroimaging aspects in migralepsy and
related conditions
There are at least ﬁfty potential cases of migralepsy in the
literature.4,6,7,12,13 However, the diagnosis in the majority of these
cases (38%) was uncertain owing to the lack of unequivocal
information. Moreover, the diagnosis inmany of the cases does not
fulﬁll the current ICHD-II criteria (30%) or is at least questionable
(28%).12 In the questionable cases, the description of the attack and
the EEG and brain imaging ﬁndings are all highly suggestive of
epileptic seizures (particularly occipital seizures). Therefore, only
4% of the cases display features supporting a diagnosis of a
migraine-triggered seizure and fulﬁll the ICHD-II criteria.12,16 In
the majority of the remaining cases, an EEG during the migraine
attack is either not available (68%) or is normal in the few cases in
which it is (4%); the main EEG abnormalities (28%) are periodic
lateralized epileptiform discharges (PLEDs) or localized theta–
delta activity.
The interictal EEG in the published migralepsy cases is normal
in some cases (32%) but displays generalized (28%) or localized
(34%) abnormalities in the majority of them. These abnormalities
are characterized by spikes, spike–wave complexes and sharp
waves, mainly localized in the temporal and/or occipital lobes.
As regards the ictal EEG abnormalities in these types of patients,
it should be borne in mind that while unequivocal epileptiform
abnormalities usually point to a diagnosis of epilepsy, the lack of a
clear epileptic spike-wave activity is frequent in other ictal
autonomic manifestations, such as Panayiotopoulos syn-
drome,18–21 as well as in patients with a deep epileptic focus
arising, for example, from the orbito-mesial frontal zone.18–21 In
such cases, ictal epileptic EEG activity might be recorded either
from the scalp or by stereo-EEG recording as a ‘‘theta’’, or even
‘‘delta’’, shape without any spike activity. Interestingly, in one
patient with headache as the sole ictal epileptic manifestation, it
was not possible to record any EEG abnormalities from the scalp.22
It has been suggested that the neurobiological explanation for
these EEG features is closely related to anatomo-neurophysiologi-
cal variables (ﬁber size, myelination and extent of polysynaptic
interconnections).18,21–23
In the cases of migralepsy in the literature, the seizures
triggered by migraine attacks are prevalently generalized tonic–
clonic seizures (GTC: 50%), though in some cases they are simple
partial seizures (SP: 8%) or complex partial seizures (CP: 16%) with
loss of consciousness.6,7,12,13 The elementary visual hallucinations
that precede pain onset in idiopathic or symptomatic occipital
seizures may represent the only symptom in such patients, thus
mimicking a typical aura migraine; these epileptic seizures with
post-ictal headache may thus be mistaken as migraine with aura,
basilar migraine, acephalalgic migraine or migralepsy. Moreover,
they are quite distinct from visual aura of migraine in their
individual elements of colour, shape, size, location, movement,
speed of development, duration and progress.8,9 Therefore,
physicians need to be fully aware of the various diagnostic criteria
if they are to choose the most appropriate treatment.
Interestingly, the patients in many so-called ‘‘ictal epileptic
headache’’ case reports are photosensitive; they usually also
present a clinical history (personal and/or familial) of epilepsy and
migraine and a photoparoxysmal EEG response.17,24–27 In two
cases, intermittent photic stimulation (IPS) evoked headache,
though it may also be possible to visually induce seizures in such
patients.17,24 The fact that headache itself is unlikely to be the sole
epileptic symptom, whether it is related to photosensitivity or not,
led to the proposal of the term ‘‘ictal epileptic headache’’.17–21
And what would the clinical and EEG features of the ictal-EEG
recording in the ‘‘ictal epileptic headache’’ cases be? Unfortunate-
ly, there is no speciﬁc EEG picture in these cases either, with
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during migraine-like complaints.10,11,17–22,24–27 These patterns
include: (i) high-voltage, rhythmic, 11–12 Hz activity with
intermingled spikes over the right temporo-occipital regions26–
27; (ii) high voltage theta activity intermingled with sharp waves
over the occipital region17 and (iii) bilateral continuous spike-and-
slow-wave discharges.25 Furthermore, a photoparoxysmal re-
sponse24 combined with complaints of a light pulsating headache
have been reported during intermittent photic stimulation.17 In
this respect, we would also like to stress the possible existence of
an isolated epileptic headache, with no associated ictal epileptic
manifestations or EEG abnormalities that can be recognized by
scalp EEG recording, whose ictal origin can be demonstrated by
depth electrode studies (see patient number 2 by Laplante et al.).22
In this regard, it should be borne in mind that in other types of
epilepsy, such as frontal lobe epilepsy, epileptic activity cannot be
detected from the scalp-EEG recording in as many as 40% of the
patients.23
It is noteworthy that complete remission of the headache and of
the epileptic abnormalities in most of these ‘‘ictal epileptic
headache’’ patients was achieved not by means of speciﬁc
antimigraine drugs, but following intravenous administration of
diazepam17,25,26 or phenytoin.27
According to the deﬁnition provided in the ICHD-II, migralepsy
is considered to be associated with MwA attacks alone. Some
authors, however, believe that a MwoA attack acts as a trigger for
an epileptic seizure.12,13 Although such events are very rare, it is
possible that the development of a MwoA attack may favor the
recurrence of a seizure according to the pathophysiological
mechanism previously described for the MwA18; furthermore,
epileptic seizures have been reported to develop later than 1 h
after the MA attack.13
Transient brain MRI abnormalities, persisting for days, have
been reported in about 6% of patients with migralepsy.28 Blood–
brain barrier damage and consequent edema have been suggested
to explain reversible radiological alterations in such cases.
In cases of migraine-triggered seizures (migralepsy), most EEG
recordings show a diffuse, irregular, high voltage, theta–delta
activity during the episodes. The EEG abnormalities were, like the
MRI alterations, transient and disappeared at the long-term
follow-up.28 Although it is not easy to interpret these ﬁndings,
one explanationmay be that they are the functional correlate of the
reversible MRI alterations observed in patients with migralepsy.
As regards the MRI features in the published cases of ‘‘ictal
epileptic headache’’, brain MRI revealed secondary brain lesions in
the right temporo-parieto-occipital region along with limited
diffusion in the right occipital region26,27 or enlarged sulci in the
right parietal region.24 However, ‘‘ictal epileptic headache’’ has
also been reported in patients with idiopathic epilepsy.17,25
As regards the therapy, the effectiveness of AEDs in the
prophylaxis phase may be explained by the anticipation of the
cortical spreading depression (CSD) event that induces secondary
trigemino-vascular system (TVS) activation and lowers the seizure
threshold in the pathophysiology of migralepsy. Sodium valproate,
topiramate and gabapentin have all proved to be effective in
double-blind placebo controlled trials, the ﬁrst two drugs having
also been approved by the U.S. Food and Drug Administration as
migraine preventive agents.5,29,30 Open trials suggest that zoni-
samide and levetiracetam may help prevent the onset of
migraine.31,32
4. Pathophysiological and genetic aspects
Although the pathophysiology of migraine-induced seizures is
still undeﬁned, it has been hypothesized that the cortical excitation
threshold in migraineurs is lower than in normal subjects, therebyfavoring the occurrence of seizure; the lower cortical excitation
threshold might be due to several conditions, alone or in
combination, such as mitochondrial defects, disturbance in
magnesium metabolism or ion channels abnormalities.33
Cortical spreading depression (CSD) seems to be the connecting
point between migraine and epilepsy.10,34,35 CSD is characterized
by a slowly propagating wave (2–6 mm/min) of sustained strong
neuronal depolarization that generates transient intense spike
activity as it progresses into the brain tissue (resulting in a
transient loss of membrane ionic gradients and in a massive surge
of extracellular potassium, neurotransmitters and intracellular
calcium), followed by neural suppression which may last for
minutes. The depolarization phase is associatedwith an increase in
regional cerebral blood ﬂow, whereas the phase of reduced neural
activity is associatedwith a reduction in blood ﬂow.36 Opinions are
still divided as to whether CSD plays a physiological or a
neuroprotective role36; it is, however, believed to cause the
activation of TVS, consisting of the cascade release of numerous
inﬂammatory molecules (sterile inﬂammation) and neurotrans-
mitters, which results in pain during the migraine attack.37 The
trigemino-vascular theory has become the most widely accepted
theory in the physiopathology of migraine,37 and the CSD is
considered to be the primary cause of TVS activation at the cortical
level.
The correlation between CSD and MwA was the ﬁrst to
emerge38; more recently, imaging studies in patients suffering
from MwoA have also highlighted the presence and role of CSD in
silent areas as an underlying mechanism.39 It should be borne in
mind that CSD is not a phenomenon that is ‘‘strictly’’ conﬁned to
the cortical structures. Indeed, cortical and subcortical areas
appear to be hierarchically divided according to how likely they are
to develop CSD,40 though the occipital lobe appears to be the area
that is most likely to be affected.41 Therefore, this hierarchical
organization in the central nervous system based on ‘‘neuronal
networks’’ (cortical and subcortical) may be prone to a greater or
lesser degree to CSD (migraine) and epileptic focal discharges
(seizures).10
On the basis of these neurophysiological data, it must be
stressed that critical alterations in headache physiopathology may
occur anywhere (cortical and/or subcortical) along the convergent
pathways (retinal afferents, dural nociceptors, brainstem nuclei,
cortical neurons or even astrocytes and blood vessels), which
conﬁrms that headache is not just a brainstem disease, but a
cortico-subcortical disease that may start at any level (cortical and
subcortical)10,42; consequently, increased awareness of this feature
of headache should serve to motivate attempts aimed at
modulating (i.e. prophylaxis) rather than merely treating this
complex disorder on an ad hoc basis.42
Going back to the relationship (at the cortical level) between
CSD and an epileptic focus, onset and propagation are triggered
when these neurophysiological events reach a certain threshold,
which is lower for CSD than for the seizure. Once the cortical event
has started, how it spreads depends on the size of the onset zone,
its velocity, semiology and type of propagation. Moreover, the
onset of CSD and that of the epileptic seizure may facilitate each
other.10,18,35,41 These two phenomena may be triggered by more
than one pathway converging upon the same destination:
depolarization and hypersynchronization.10,18,35,41
The triggering causes, which may be environmental or
individual (genetically determined or not), result in a ﬂow of ions
that mediates CSD, through neuronal and glial cytoplasmic bridges
(intracellular gap-junctions) rather than through interstitial
spaces, as usually occurs in the spreading of epileptic sei-
zures.10,18,21 The threshold required for the onset of CSD (migraine)
is likely to be lower than that required for the epileptic seizure. In
this regard, a ‘‘migraleptic’’ event is very rare because the threshold
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requested for CSD onset. Furthermore, recurrent seizures might
also predispose patients to CSD, thereby increasing the occurrence
of a peri-ictal migraine-type headache; moreover, accordingly, in
the clinical contest a post-ictal headache in epileptic patients is
muchmore common than all the other types (pre-ictal and ictal) of
peri-ictal headache.10,18,21
It is well known that CSD leads to signiﬁcant changes in the
composition of extracellular ﬂuid, including increases in glutamate
and potassium ions; these changes, in turn, result in hyperexcit-
ability and may lower the seizure threshold.43,44 A paroxysmal
change in cortical neuronal activity may occur during a migraine
attacks or epilepsy seizure; hyperexcitation occurs in epilepsy,
whereas in migraine hypoexcitation and hyperexcitation occur
sequentially as rebound phenomena (spreading depression).35
Much remains to be understood of the pathophysiology of these
diseases, though it is clear that glutamate metabolism,45 serotonin
metabolism,46 dopamine metabolism47 and ion channel function
are impaired in both.48 Mutations in genes coding for ion channels,
such as those for sodium, potassium and chloride, cause abnormal
synchronization or increase the excitability of cortical neurons.49
No speciﬁc data are available on genetic aspects of migralepsy.
The best studies on genetic abnormalities that lead to epilepsy and
migraine regard Familial Hemiplegic Migraine (FHM),50 a rare
autosomal dominant subtype of migraine with aura characterized
by unilateral motor weakness that occurs during the migraine
aura.16 The FHM1 gene CACNA1A codes for the pore-forming
subunit of Cav2.1 P/Q-type calcium channels and is located on the
short arm of chromosome 19; at present, 17 different mutations in
this gene are known.51 CACNA1A mutations might very well
inﬂuence cortical spreading depression, since P/Q-type calcium
channels mediate glutamate release in cortical neurons.49 The
FHM2 gene ATP1A2 is located on the long arm of chromosome 1.52
It codes for the a2 subunit of sodium/potassium ATPase, which is
responsible for pumping potassium ions into the cell and sodium
ions out of the cell.53 Impaired sodium/potassium balance is
known to cause cortical spreading depression. As in FHM1, various
mutations in the ATP1A2 gene have been reported.51 Mutations
have recently been found in FHM families (FHM3), in the SCN1A
gene located on 2q24, which is associated with epilepsy.54 SCN1A
mutations can cause genetic epilepsy with febrile convulsions
(GEFS+), Dravet syndrome and other rare epilepsy syndromes.55
More than 150 different mutations in SCN1A have been described
in families with epilepsy.56
Several other genetic ﬁndings pointing to a link between
migraine and epilepsy have been reported. They includemutations
on SLC1A3, a member of the solute carrier family that encodes
excitatory amino acid transporter 1,57 POLG58, C10 and F259, which
encode mitochondrial DNA polymerase and helicase twinkle. A
genetic defect in ion channels therefore seems to be a shared
pathophysiological mechanism of migraine and epilepsy. Voltage-
gated ion channels are part of an extensive signaling pathway that
affect neuronal excitability through various mechanisms60; in
addition, these channels can directly activate enzymes linked to
the signaling pathway and serve as cell adhesion molecules or
components of the cytoskeleton, while their activity is known to
alter the expression of other speciﬁc genes. Although it is likely
that voltage-gated ion channels are critically positioned in the
pathways associated with migraine and epilepsy, the contribution
of numerous other genes/proteins in the pathways of migralepsy
warrants further investigation.
5. Conclusions
The classiﬁcation of ‘‘migralepsy’’ and related conditions
(hemicrania epileptica and ictal epileptic headache) represents a‘‘hot topic’’ that warrants revision tomore accurately represent the
relationship between migraine/headache and epilepsy. Indeed,
migralepsy is a rare, ill-deﬁned nosologic entity. In the majority of
cases described in the literature, the clinical features are suggestive
of occipital lobe seizures, though the data available are not
sufﬁcient to draw ﬁrm conclusions. Related conditions, such as
‘‘hemicrania epileptica’’ (coded in ICHD II at point 7.6.1) and ‘‘ictal
epileptic headache’’ (recently proposed though not recognized or
classiﬁed yet) also need to be deﬁnedmore clearly. To date, neither
the International Headache Society nor the International League
against Epilepsy mention that headache/migraine may, on
occasion, be the sole ictal epileptic manifestation; this also applies
to the ICHD-II criteria as regards the classiﬁcation of ‘‘hemicrania
epileptica’’. Nonetheless, a growing body of evidence indicates that
headache per se may represent an epileptic seizure, and that it
may, in rare cases, even be the sole ictal manifestations of epilepsy.
This may result from an interplay between the epileptic focus and
CSD, which may in turn activate a common ﬁnal pathway of pain
triggered by the TVS. These ﬁndings also highlight the diagnostic
importance of EEG recording during the attacks for classiﬁcation
purposes. Our personal opinion, which is based on the knowledge
currently available and the clinical experiences reported here, is
that the existence of migralepsy (coded in ICHD-II as 1.5.5
‘‘migraine-triggered seizure’’) is, despite being theoretically
possible, highly unlikely. We therefore propose relocating the
term ‘‘migralepsy’’ (‘‘migraine-triggered seizure’’) in the appendix
of both classiﬁcations (ICHD-II and ILAE) until clear evidence
emerges of its existence. Moreover, we also believe that ‘‘ictal
epileptic headache’’ should be used to classify those rare events in
which headache represents the sole ictal epileptic manifestation.
By contrast, the term ‘‘hemicrania epileptica’’ should be main-
tained in the ICHD-II and introduced into the ILAE, and be used to
classify all cases in which an ‘‘ictal epileptic headache’’ ‘‘coexists’’
and is associated either synchronously or sequentially with other
ictal sensory-motor events.
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